COVID-19 With Preexisting Hypercoagulability Digestive Disease.

Jiang, Mingshan; Mu, Jingxi; Shen, Silan; Zhang, Hu

Jiang, Mingshan; Mu, Jingxi; Shen, Silan; Zhang, Hu.

Jiang M; Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
Mu J; Center for Inflammatory Bowel Disease, West China Hospital, Sichuan University, Chengdu, China.
Shen S; Laboratory of Inflammatory Bowel Disease, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
Zhang H; Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.

Front Med (Lausanne) ; 7: 587350, 2020.

Artículo en Inglés | MEDLINE | ID: covidwho-1058422

ABSTRACT

ABSTRACT

The outbreak of coronavirus disease of 2019 (COVID-19) has become a global public health and economic crisis. The advent of hypercoagulability and thrombotic complications can substantially influence the prognosis of COVID-19 patients. In this review, we elaborate on the clinical findings, potential underlying pathogenesis, and therapeutic strategy of hypercoagulability and thromboembolism in COVID-19, particularly focusing on the COVID-19 patients with preexisting digestive hypercoagulability disease.

Palabras clave

SARS-CoV-2; coronavirus disease 2019; hypercoagulability; inflammatory bowel disease; thromboembolism

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Tipo de estudio: Estudio pronóstico Idioma: Inglés Revista: Front Med (Lausanne) Año: 2020 Tipo del documento: Artículo País de afiliación: Fmed.2020.587350

Similares

MEDLINE

LILACS

LIS

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google